+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects



Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects



Expert Review of Clinical Pharmacology 2(4): 405-421



Drug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB through a good control program based on directly observed treatment, short-course, is of paramount importance. Established multidrug-resistant (MDR)-TB requires alternative specific chemotherapy, comprising drugs with higher cost and greater toxicity delivered on a programmatic basis. The development of new anti-TB drugs would help to prevent and treat MDR-TB. Notably, moxifloxacin and gatifloxacin are being tested for shortening treatment in Phase III trials, while three novel compounds, TMC-207, OPC-67683 and PA-824 are in Phase II studies for both drug-susceptible and drug-resistant disease. The roles of surgery and immunotherapy in the management of MDR-TB require further evaluation. The recent emergence of extensively drug-resistant TB poses a serious challenge to the global control of TB. In order to combat extensively drug-resistant TB, strengthening of directly observed treatment, short-course and drug-resistance programs, alongside other strategies, including the development of newer diagnostics and drugs, is mandatory.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056676003

Download citation: RISBibTeXText

PMID: 22112184

DOI: 10.1586/ecp.09.19


Related references

Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Kekkaku 86(1): 9-16, 2011

Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clinical Medicine 14(3): 279-285, 2014

The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology 18(5): 289-291, 2008

Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis current standards and challenges. Canadian Journal Of Infectious Diseases & Medical Microbiology: 2, 169-172, 2008

Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Canadian Journal of Infectious Diseases and Medical Microbiology 19(2): 169-172, 2009

Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected persons: what does the future hold in store?. Journal of Infectious Diseases 198(11): 1577-1578, 2008

Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. Journal of Infection and Public Health 7(2): 75-91, 2014

Multidrug-resistant tuberculosis in panama is driven by clonal expansion of a multidrug-resistant Mycobacterium tuberculosis strain related to the KZN extensively drug-resistant M. tuberculosis strain from South Africa. Journal of Clinical Microbiology 51(10): 3277-3285, 2014

Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microbial Drug Resistance 16(1): 81-86, 2010

Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrobial Agents and ChemoTherapy 53(8): 3353-3356, 2009

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet. Infectious Diseases 17(7): 707-715, 2017

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in adolescent patients. Pediatric Infectious Disease Journal 33(6): 657-659, 2015

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases 47(4): 496-502, 2008

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infection, Genetics and Evolution 12(4): 686-694, 2012

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial ChemoTherapy 64(2): 388-391, 2009